Eos

It is our mission to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. Dxcover are an award-winning team, dedicated to developing liquid biopsies for early detection of cancer and other diseases. A University of Strathclyde spinout in 2019 under the name ClinSpec Diagnostics, and rebranded as Dxcover Limited in 2021. To date, Dxcover have secured £5.1m of funding, and have successfully completed two ground-breaking clinical studies on detection of brain cancer and are currently developing our platform for the detection of commonly occurring cancers.

Penrhos Bio develops innovative, organically inspired substances aimed at combating microbial biofilms and addressing microbial contamination. Their bioscience platform provides a sustainable and low-toxicity alternative to traditional biocides, targeting bacterial communication and quorum sensing through various mechanisms. This approach offers effective solutions across multiple sectors, including consumer products, healthcare, and industrial applications, specifically benefiting industries such as marine, textile, paper, household cleaning, and medical fields. By focusing on environmentally friendly methods, Penrhos Bio addresses significant challenges posed by microbial contamination.

Carcinotech is focused on treating cancers and is based at the Roslin Innovation Centre on the outskirts of Edinburgh.

Wobble Genomics is a biotechnology firm focused on enhancing the efficiency of RNA and DNA sequencing to facilitate the discovery and detection of nucleic acid biomarkers. The company employs a blend of biochemistry and bioinformatics to achieve unprecedented sensitivity and accuracy in identifying novel biomarkers. By optimizing sampling efficiency during sequencing, Wobble Genomics aims to reduce costs for medical researchers, thereby advancing the field of genomic analysis and improving diagnostic capabilities.

It is our mission to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. Dxcover are an award-winning team, dedicated to developing liquid biopsies for early detection of cancer and other diseases. A University of Strathclyde spinout in 2019 under the name ClinSpec Diagnostics, and rebranded as Dxcover Limited in 2021. To date, Dxcover have secured £5.1m of funding, and have successfully completed two ground-breaking clinical studies on detection of brain cancer and are currently developing our platform for the detection of commonly occurring cancers.

RAB Microfluidics specializes in developing innovative lab-on-a-chip technology aimed at transforming oil analysis processes. By utilizing patented microfluidic technology, the company offers real-time diagnostics for lubricated machinery, enabling early detection of potential failures and preventing costly equipment breakdowns. This dynamic approach provides clients with laboratory-quality data and actionable insights for effective asset condition management, significantly reducing costs compared to traditional methods. Founded on a decade of research from the University of Aberdeen, RAB Microfluidics is recognized as a pioneer in microfluidic technology for oil applications in Europe. With a dedicated advisory team boasting over 60 years of expertise, the company is committed to addressing the needs of diverse industries, including oil and gas, aerospace, and power generation, by making oil testing mobile, rapid, and routine.

It is our mission to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. Dxcover are an award-winning team, dedicated to developing liquid biopsies for early detection of cancer and other diseases. A University of Strathclyde spinout in 2019 under the name ClinSpec Diagnostics, and rebranded as Dxcover Limited in 2021. To date, Dxcover have secured £5.1m of funding, and have successfully completed two ground-breaking clinical studies on detection of brain cancer and are currently developing our platform for the detection of commonly occurring cancers.

GM Flow offer a range of flow measurement services and products, to the oil and gas industry.

Rooser connects seafood buyers and suppliers across Europe, providing them with the tools they need to trade efficiently, negotiate prices, and process deliveries. Rooser is located in Edinburgh, Scotland.